Company Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 1986 |
| IPO Date | Mar 3, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 536 |
| CEO | Jon Stonehouse |
Contact Details
Address: 4505 Emperor Boulevard, Suite 200 Durham, North Carolina 27703 United States | |
| Phone | 919 859 1302 |
| Website | biocryst.com |
Stock Details
| Ticker Symbol | BCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000882796 |
| CUSIP Number | 09058V103 |
| ISIN Number | US09058V1035 |
| Employer ID | 62-1413174 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jon P. Stonehouse | Chief Executive Officer, President and Executive Director |
| Anthony J. Doyle | Senior Vice President, Chief Financial Officer and Interim Principal Accounting Officer |
| Alane P. Barnes | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Helen M. Thackray FAAP, M.D. | Chief Research and Development Officer |
| Charles K. Gayer | Senior Vice President and Chief Commercial Officer |
| John D. Bluth | Chief Communications Officer |
| Stephanie Angelini | Chief People Officer |
| Dr. William P. Sheridan MBBS | Chief Development Officer |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer |
| Jinky Ang Rosselli | Chief Data and Insights Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 5, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 17, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 2, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 6, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |